Skip to main
OPK

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health Inc. reported a significant 20% growth in volumes for its 4Kscore test, contributing to a 5.3% increase in revenue within the non-oncology segment of its lab business. Furthermore, BARDA-related revenue rose to $8.2 million, reflecting a positive trajectory for the company’s pharmaceutical products segment, with ongoing expectations for margin improvements and operational enhancements in the diagnostics area. The company’s EPS also demonstrated resilience, reporting $0.03, supported by a one-time gain from a lab business divestiture, indicating an expansion in its overall operational activity and potential for future growth.

Bears say

OPKO Health's recent financial performance reflects significant challenges, particularly in its diagnostics segment, which recorded an $18.3 million operating loss for the quarter. Additionally, Q3 revenue fell short of expectations and was negatively impacted by lower gross margins and elevated operating expenses, leading to a disappointing fiscal year 2026 financial guidance. The pharmaceutical segment also faced setbacks, with product revenue declining to $37.7 million, primarily due to lower sales volumes and unfavorable product mix, further exacerbating the company's overall financial outlook.

OPKO Health (OPK) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Hold based on their latest research and market trends.

According to 2 analysts, OPKO Health (OPK) has a Hold consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.